Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03764813
Other study ID # 22139/18ID:1916
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 5, 2018
Est. completion date August 2, 2019

Study information

Verified date August 2021
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Repeated transfusions have been associated with very poor outcome of preterm infants. Fetal hemoglobin (HbF) and adult Hb (HbA) have different affinity for oxygen. The high level of adult Hb may contribute to exacerbating the oxidative damage responsible for prematurity diseases. The investigators hypothesized that transfusing red blood cells (RBC) obtained from allogeneic cord blood (CB) of healthy full-term babies (which contains almost exclusively HbF) may prevent the non-physiological decrease of HbF in premature neonates, likewise protecting them from oxygen radical diseases. Cord blood transfusion in preterms - CB TRIP - is a monocentric prospective nonrandomized study aimed to monitor HbF levels in preterm neonates receiving RBC transfusions from either umbilical blood of full-term healthy babies (CB-RBC) and/or from adult donors (A-RBC).


Description:

Preterm neonates enrolled in this study are monitored for the level of HbF on capillary blood samples, from birth to the week 32 of postmenstrual age (PMA). To fulfill the RBC transfusion requirements, RBC concentrates obtained from umbilical blood of full-term healthy babies are utilized, if available; otherwise, RBC concentrates from adult donors are assigned. For every week of PMA, neonates undergo a minimum of three HbF determinations, and the median values are considered.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date August 2, 2019
Est. primary completion date August 2, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: preterm neonates born at PMA =30 weeks and/or with birth weight =1000 g born at the delivery room of Fondazione Policlinico Universitario A. Gemelli candidate to receive one or more RBC unit transfusion. Exclusion Criteria: One or more of the following criteria Maternal-fetal immunization Hydrops fetalis Major congenital malformations associated or not with genetic syndromes Previous transfusions Hemorrhage at birth Congenital infections (such as infections from TORCH complex) Out-born infants The health care team deems it inappropriate to approach the infant's family for informed consent

Study Design


Locations

Country Name City State
Italy Fondazione Policlinico Universitario A. Gemelli IRCCS Roma RM
Italy Fondazione Policlinico Universitario A.Gemelli IRCCS Rome

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Bianchi M, Giannantonio C, Spartano S, Fioretti M, Landini A, Molisso A, Tesfagabir GM, Tornesello A, Barbagallo O, Valentini CG, Vento G, Zini G, Romagnoli C, Papacci P, Teofili L. Allogeneic umbilical cord blood red cell concentrates: an innovative blood product for transfusion therapy of preterm infants. Neonatology. 2015;107(2):81-6. doi: 10.1159/000368296. Epub 2014 Nov 15. — View Citation

Bianchi M, Papacci P, Valentini CG, Barbagallo O, Vento G, Teofili L. Umbilical cord blood as a source for red-blood-cell transfusion in neonatology: a systematic review. Vox Sang. 2018 Nov;113(8):713-725. doi: 10.1111/vox.12720. Epub 2018 Oct 16. — View Citation

dos Santos AM, Guinsburg R, de Almeida MF, Procianoy RS, Leone CR, Marba ST, Rugolo LM, Fiori HH, Lopes JM, Martinez FE; Brazilian Network on Neonatal Research. Red blood cell transfusions are independently associated with intra-hospital mortality in very low birth weight preterm infants. J Pediatr. 2011 Sep;159(3):371-376.e1-3. doi: 10.1016/j.jpeds.2011.02.040. Epub 2011 Apr 13. — View Citation

Stutchfield CJ, Jain A, Odd D, Williams C, Markham R. Foetal haemoglobin, blood transfusion, and retinopathy of prematurity in very preterm infants: a pilot prospective cohort study. Eye (Lond). 2017 Oct;31(10):1451-1455. doi: 10.1038/eye.2017.76. Epub 2017 May 26. — View Citation

Valieva OA, Strandjord TP, Mayock DE, Juul SE. Effects of transfusions in extremely low birth weight infants: a retrospective study. J Pediatr. 2009 Sep;155(3):331-37.e1. doi: 10.1016/j.jpeds.2009.02.026. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Median Percentage of HbF at 32 Weeks of Post Menstrual Age The HbF level was determined by high-performance liquid chromatography and was expressed as percentage of total Hb, calculated as the sum of fetal and adult Hb, according to the formula: HbF= [HbF/ (FHbA1 + HbA2 + HbF)]. HbF. From study entry to the completion of postmenstrual age of 32 weeks
Secondary Post-transfusion Hematocrit (Htc) Change Change from baseline of Htc observed after either adult-RBC or cord-RBC transfusions. To this purpose, analysis was carried out between the two groups of RBC transfusions and patients were accordingly redistributed. From enrollment to last HbF assessment occurring at 36 weeks, discharge or death
Secondary Intervals Between Transfusions Number of days between two consecutive transfusions.To this purpose, analysis was carried out between the two groups of RBC transfusions and patients were accordingly redistributed. From enrollment to the last HbF assessment occurring at 36 weeks, discharge or death
Secondary Median Percentage of HbF at Last Assessment Median percentage of HbF at last HbF assessment. The last HbF measure was obtained at the completion of the 36 week of age, discharge or death. From enrollment to the last HbF assessment occurring at 36 weeks, discharge or death
See also
  Status Clinical Trial Phase
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Recruiting NCT06403163 - Transfusion Surveillance in Anaesthesia
Not yet recruiting NCT02587845 - Use of Transexamic Acid in Hip Replacement Phase 3
Completed NCT03365999 - Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. Phase 2
Completed NCT03784794 - Patient Blood Management for Massive Obstetric Hemorrhage N/A
Not yet recruiting NCT02139995 - West-China Transfusion Score for Critically-ill Patients Phase 3
Completed NCT04513249 - Effects of Therapeutic Plasmaexhange on Viscoelastic Tests in Non-coagulopathic Patients
Not yet recruiting NCT03934112 - Impact of Transfusional Practice on the Morbidity and Mortality of Patients in Intensive Care Unit
Completed NCT03394274 - Restrictive Versus Liberal Transfusion, Major Surgeries N/A
Not yet recruiting NCT06399536 - Individualized ANH for Non-cardiac Surgery N/A
Withdrawn NCT04388722 - Monitoring Noninvasively for Infusion and Transfusion Optimization N/A
Completed NCT03476005 - Proficiency Based Training to Investigate WBIT N/A
Recruiting NCT03999229 - S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion Phase 1
Not yet recruiting NCT04413721 - Effects of Packed Red Blood Cell Storage Duration on Pediatric Living Donor Liver Transplantation N/A
Recruiting NCT02461264 - Transfusion Strategy in Hematological Intensive Care Unit Phase 3
Terminated NCT01915654 - Impact of RBC Transfusion Less Than 14 Days on Morbidity and Mortality in Cardiac Surgical Patients N/A
Not yet recruiting NCT05696210 - Evaluation of the 1-year Prognosis of Patients Under Veno-arterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock With Blood Transfusion Requirement
Completed NCT04286984 - Implementation of a Patient Blood Management Program in Gastric Cancer Surgery
Withdrawn NCT04383756 - Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation Early Phase 1
Completed NCT03815773 - PRospective Multicenter Observational Study on Transfusion Practice in Vv-ECMO Patients: The PROTECMO Study